Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Meloxicam Capsules vs Tablets
NCT03684265Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of meloxicam in osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve from 0 to Last Quantifiable Data Point at 72 hours and Maximum Measured Concentration at 72 hours. Started Oct 2018; status: completed.
02
Drugs
meloxicam
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT03684265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03684265.